Effect of daglipzin combined with routine treatment on renal function, urinary podocyte-related proteins and inflammatory factors in patients with early diabetic kidney disease
10.3760/cma.j.cn431274-20240521-00827
- VernacularTitle:达格列净联合常规治疗对早期糖尿病肾病患者肾功能、尿足细胞相关蛋白和炎症因子的影响
- Author:
Jian YANG
1
;
Jing FAN
;
Jintao LI
;
Meilan ZHOU
Author Information
1. 宝鸡市中医医院肾内科，宝鸡 721000
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Daglipzin;
Kidney function;
Uropodocyte associated protein;
Inflammatory factors
- From:
Journal of Chinese Physician
2025;27(7):1030-1034
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of daglipzin combined with routine treatment on renal function, urinary podocyte-related protein (PCX) and inflammatory factors in patients with early diabetic kidney disease (DKD).Methods:A total of 120 early DKD patients in Baoji Traditional Chinese Medicine Hospital from March 2021 to December 2023 were prospectively collected and divided into two groups (observation group and control group) according to the random number table method, with 60 cases in each group. All patients received routine treatment. The observation group was additionally treated with daglipzin, while the control group was treated with metformin. Before and after treatment, the renal function indexes [vascular cell adhesion molecule-1 (VACM-1), creatinine (Cr), blood urea nitrogen (BUN)], urinary podocalyxin (PCX), and inflammatory factors [homocysteine (Hcy), high-sensitivity C-reactive protein (hs-CRP), macrophage migration inhibitory factor (MIF), tumor necrosis factor-α (TNF-α)] were detected in both groups. Meanwhile, the glucose metabolism levels [fasting blood glucose (FBG), glycosylated hemoglobin A 1c (HbA 1c)] and the occurrence of adverse reactions were compared between the two groups. Results:There were no significant differences in renal function, urinary PCX, glucose metabolism indexes, and inflammatory factor levels between the two groups before treatment (all P>0.05). After treatment, serum levels of VACM-1, BUN, Cr, hs-CRP, TNF-α, MIF, Hcy, FBG, HbA 1c, and urinary PCX in both groups were lower than those before treatment (all P<0.05). Moreover, the serum levels of VACM-1, BUN, Cr, hs-CRP, TNF-α, MIF, Hcy, FBG, HbA 1c, and urinary PCX in the observation group after treatment were lower than those in the control group (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups ( P>0.05). Conclusions:Compared with metformin, daglipzin combined with routine treatment can improve renal function, reduce urinary PCX and inflammatory factor levels in patients with early DKD, which has certain clinical application value.
